Abeona Therapeutics, Inc. ABEO

- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage

Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.

Healthcare stocks were edging higher pre-bell Wednesday, with the State Street Health Care Select Se

CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified c

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026: Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.Morgan Stanley 2

On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the bumps that come with it. ZEVASKYN, its cell therapy for a severe skin disease called recessive dystrophic epidermolysis bullosa, brought in $11.4 million in revenue for the quarter, and the number […]

Despite manufacturing hiccups and patient cancellations, the company expands its treatment center network and secures CMS NTAP status to bolster market access.

By David Bautz, PhD NASDAQ: ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Five Patients Treated in 2Q26; 12 Patients Treated in Total Thus Far Abeona Therapeutics, Inc (NASDAQ: ABEO) is continuing the commercial launch of Zevaskyn®, with five patients treated in the second quarter of 2026, up 67% sequentially from three patients in the first quarter of 2026, followed by three additional

Moby summary of Abeona Therapeutics Inc.'s Q2 2026 earnings call

- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process – - $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 – CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics

CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide a corporate update. Abeona will announce its financial results for this period in a press release to be issued prior to the call. To access the live conference call, please dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (internat